Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sumatriptan effects on 5-HT1B receptor and CBF
NCT02932488Phase 1Terminated
- Start
- Sep 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sumatriptan in migraine. Primary endpoints: Changes in 5-HT1B receptor binding as measured with [11C]AZ10419369 and Changes in cerebral blood flow measured with pseudo continuous Arterial Spin Labeling. Started Sep 2016; status: terminated.
02
Drugs
sumatriptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02932488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932488.